Background Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target.
Introduction
Statins reduce LDL cholesterol concentration by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), leading to a proportionate reduction in cardiovascular disease (CVD) risk. [1] [2] [3] [4] Consequently, statins have become the most widely prescribed drug class: over 25% of US adults aged at least 45 years (30 million individuals) received these drugs from 2005 to 2008 5 and an estimated 56 million might be eligible for statin treatment under new guidelines. 6 A meta-analysis of randomised controlled trials of statins recently identifi ed a higher risk of type 2 diabetes mellitus from statin treatment compared with placebo or standard care, 7 which was dose related. 8 These fi ndings prompted a US Food and Drug Administration Drug Safety Communication in 2012 9 and a change to statin safety labelling. Subsequently, observational studies have also reported a higher risk of type 2 diabetes with statin treatment compared with individuals not taking statins. [10] [11] [12] Although type 2 diabetes is a cardiovascular risk factor, there remains a net benefi t of statin treatment for prevention of CVD 3 including among patients with diabetes. 4 The mechanism underlying the glucose-raising eff ect of statins is of interest. A potential explanation in observational studies is that statin users adopt a less healthy lifestyle than individuals not taking statins, but this explanation is unlikely in masked treatment trials, which suggests that the eff ect is pharmacological. However, whether the glucose-raising eff ect of statins is explained by the same mechanisms as for LDL cholesterol lowering (ie, HMGCR inhibition) or by one of the proposed pleiotropic eff ects of statins 13, 14 (eg, mediated through isoprenoid intermediates and G-protein signalling 15 ) is uncertain.
To investigate the mechanism underlying the glucose-raising eff ect of statins, we used the mendelian randomisation principle, 16, 17 with common variants in the gene encoding a drug target as uncon founded, unbiased proxies for pharmacological action on that target. 18 We identifi ed single nucleotide poly morphisms (SNPs) in the HMGCR gene and examined their associations with bodyweight, body-mass index (BMI), waist circumference, plasma insulin and glucose, and risk of type 2 diabetes. Associations with these phenotypes would implicate a mechanism involving HMGCR inhibition. To test the correspondence of genetic and pharmacological eff ects, we updated a meta-analysis of the eff ect of statins on type 2 diabetes risk in randomised trials, and added new information on bodyweight.
Methods

Genetic studies
We selected as instruments two SNPs (rs17238484 and rs12916) in the HMGCR gene on the basis of genetic associations with LDL cholesterol in the Whitehall II study (n=4678) 19 using the IBC HumanCVD BeadChip (Cardiochip; Illumina, San Diego CA, USA) (appendix). 20 Both were subsequently associated with LDL cholesterol at a genome-wide level of signifi cance, 21 with strong associations in the largest genome-wide study of lipids so far (rs17238484 p=1·35 × 10 -²¹; rs12916 p<1·00 × 10 -³⁰). 22 Data were available for the greatest number of individuals for the rs17238484 SNP, and this was used for the principal analysis; a subsidiary analysis used the rs12916 SNP. To investigate potential confounding by linkage disequilibrium between our lead SNPs and others in nearby genes, we assessed the association of the HMGCR SNPs with hepatic genome-wide expression data (appendix). If the lead SNPs were in strong linkage disequilibrium with nearby loci, those genes might confound the noted eff ects of HMGCR genotype on measured phenotypes. 23 In observational population studies (appendix) with genotype data for the rs17238484 SNP (or a proxy in strong linkage disequilibrium, r²>0·85), we included individuals of European descent for whom data were available on one or more phenotype of interest. In a secondary analysis, we included data from a subset of studies with data available on the rs12916 SNP or a suitable proxy.
Biomarkers included in the genetic analysis were total cholesterol, LDL cholesterol, non-HDL cholesterol, bodyweight, BMI, waist and hip circumferences, waist:hip ratio, height, plasma glucose, and plasma insulin (appendix). The primary disease outcome was type 2 diabetes, including prevalent (occurring before study baseline) as well as incident cases (occurring subsequently; appendix). In the mendelian random isation paradigm, the intervention is the naturally randomised allocation of genotype, which occurs at conception and exerts its eff ect from that point throughout the lifetime of the individual. Therefore, events prevalent at the time of recruitment to genetic studies are nevertheless incident from the perspective of the time of the genotypic randomisation and can be included in the genetic analysis. Thus, for the genetic analysis, both prevalent and incident cases were included to maximise power.
All studies contributing data to these analyses were approved by their local ethics committees, as described in the published fi ndings of each study (appendix).
Meta-analysis of statin trials
We updated our two previous summary-level metaanalyses 7,8 on the association of statin treatment with incident type 2 diabetes in cardiovascular prevention trials of at least 1000 participants, followed up for at least 1 year. The appendix contains details of the exclusion criteria and trials.
Investigators from 20 eligible trials with data on incident type 2 diabetes were contacted for information on bodyweight change during follow-up by treatment allocation, which was used as a coprimary outcome. 15 trials provided data on bodyweight at baseline and at the last visit attended among individuals free from type 2 diabetes at baseline. Two trials (ALLHAT 24 and A to Z 25 ) did not measure bodyweight sequentially, and bodyweight data were unavailable from the remaining three trials (appendix). Data were also analysed separately for participants not experiencing any primary cardiovascular outcome (according to trial-specifi c defi nitions) to exclude the possibility that the eff ect of statin treatment on bodyweight was limited to participants experiencing cardiovascular events.
Changes in LDL cholesterol in each treatment group at 1 year were available from the Cholesterol Treatment Trialists' Collaboration meta-analysis for 18 trials, 1 whereas data for mean changes in LDL cholesterol during two trials were taken from the primary publications. 26, 27 Information about plasma glucose and insulin concentrations, BMI, waist circumference, and waist:hip ratio was unavailable from the trials.
Statistical analysis
For the genetic studies, we assessed study-specifi c associations of rs17238484 and rs12916 with each continuous trait using univariate linear regression models. 
E Associations with risk of type 2 diabetes
Waist circumference Hip circumference Waist:hip ratio Plasma glucose and insulin were analysed on the natural logarithmic scale because of their skewed distributions, and we present proportional diff erences in geometric means per allele. The rs17238484-G allele and rs12916-T allele were each associated with lower LDL cholesterol concentration and were designated the eff ect alleles, to facilitate direct comparison with statin treatment.
We assessed associations of the rs17238484 and rs12916 SNPs with type 2 diabetes risk using univariate logistic regression models to estimate the odds ratio (OR) per LDL-lowering allele. We combined within-study estimates using fi xed-eff ects and random-eff ects meta-analyses, with heterogeneity quantifi ed by the I² statistic. 28 Heterogeneity between subgroups was assessed using meta-regression. All genetic analyses were done using a prespecifi ed routine in Stata version 12.1, which was translated for use in SPSS, SAS, and R where necessary.
To corroborate our genetic fi ndings, we examined the associations of the two lead SNPs in a large genome-wide association study of BMI, 29 a Metabochip analysis of plasma insulin, 30 and a genome-wide association and Metabochip analysis of type 2 diabetes. 31 In the meta-analysis of statin trial data, we synthesised within-trial ORs for type 2 diabetes during follow-up in participants free from type 2 diabetes at baseline and within-trial mean diff erences in bodyweight change between treatment groups, calculated as the diff erence from baseline to fi nal visit, using random-eff ects and fi xed-eff ects meta-analyses. We undertook meta-regression analyses of the associations of new-onset type 2 diabetes and bodyweight change with change in LDL cholesterol at 1 year and with follow-up duration. We assessed inter-study heterogeneity using the I² statistic and used Stata version 10.1 for trial-related analyses.
Role of the funding source
The funding sources had no role in study design, data collection, data analysis, data interpretation, the writing of the report, or the decision to submit for publication. DIS, DP, ADH, and NS had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Of 38 Cardiochip SNPs within 55 kb of the HMGCR gene, seven met prespecifi ed criteria for instrument selection (appendix), of which all but the two selected, rs17238484 and rs12916, were in strong linkage disequilibrium (r²>0·9; appendix). Gene expression data for rs17238484 were unavailable, but the T allele of rs12916 was associated with lower hepatic HMGCR expression (p=1·30 × 10 -⁵) but not with expression of adjacent genes (appendix).
Data for up to 195 444 individuals (43 studies) for the HMGCR rs17238484 SNP and 94 652 individuals (21 studies) for the rs12916 SNP (or suitable proxies in studies in which these were not directly measured) contributed to the analysis of genetic associations with biomarkers and outcomes. The mean age of study participants was 59 years (range 26-75; appendix).
The association of the rs17238484 genotype with circulating concentrations of major lipid fractions followed an additive model in the meta-analysis of available data (fi gure 1A). Each additional rs17238484-G allele was associated with 0·06 mmol/L (95% CI 0·05-0·07) lower LDL cholesterol (p=1·34 × 10 -³⁵; 101 919 individuals, 26 studies), 0·07 mmol/L (0·06-0·08) lower total cholesterol (p=6·46 × 10 -³⁶; 117 545 individuals, 30 studies), and 0·07 mmol/L (0·06-0·08) lower non-HDL cholesterol (p=3·32 × 10 -³⁰; 103 375 individuals, 27 studies). The association of genotype with LDL cholesterol concentration was consistent between subgroups (data available in up to 29 studies, 116 327 individuals), with all meta-regression p values greater than 0·05 (appendix). Associations of rs12916 with plasma lipids were directionally concordant with rs17238484 and of similar magnitude (appendix).
The rs17238484-G allele was associated with 1·62% (95% CI 0·53-2·72; p=0·004) higher plasma insulin concentration (37 453 individuals, 12 studies) and with higher plasma glucose concentration (0·23%, 0·02-0·44; p=0·03; 73 490 individuals, 23 studies; fi gure 1B). Each rs17238484-G allele was also associated with 0·30 kg higher bodyweight (95% CI 0·18-0·43; p=3·15 × 10 -⁶; 143 113 individuals, 30 studies) and 0·11 kg/m² higher BMI (0·07-0·14; p=1·77 × 10 -⁷; 152 004 individuals, 32 studies; fi gure 1C), but not with height (p=0·23; 77 291 individuals, 23 studies; appendix). Each additional rs17238484-G allele was associated with greater waist circumference (0·32 cm, 95% CI 0·16-0·47; p=8·32 × 10 -⁵; 69 163 individuals, 19 studies), hip circumference (0·21 cm, 0·10-0·32; p=1·67 × 10 -⁴; 69 159 individuals, 19 studies), and waist:hip ratio (0·001, 0·0003-0·002; p=0·01; 95 496 individuals, 23 studies; fi gure 1D). The rs12916 SNP showed directionally concordant associations with these biomarkers (appendix). Additive association patterns were noted with all these traits, and no diff erences in the rs17238484 SNP eff ect occurred between subgroups (all meta-regression p values >0·05; appendix). The appendix shows estimates from random-eff ects meta-analyses.
Public domain data from a meta-analysis of genome-wide association studies of BMI 29 and an Illumina Metabochip-based 32 analysis of plasma insulin 30 revealed directionally concordant associations of the rs17238484 and rs12916 SNPs or suitable proxies with both these traits: log plasma insulin rs12916 β 0·007 (95% CI 0·002-0·012; p=4·72 × 10 -³) and rs17238484 β 0·01 (0·004-0·016; p=5·92 × 10 -⁴); and BMI rs17238484 p=9·28 × 10 -6 and rs12916 p=1·45 × 10 -⁴. Associations of both SNPs with fasting insulin were attenuated to the null after adjustment for BMI in the same datasets (rs17238484 p=0·74; rs12916 p=0·63).
In 26 236 cases and 164 842 controls in 35 population studies, the HMGCR rs17238484-G allele, which was associated with lower LDL cholesterol and higher bodyweight and BMI, seemed to be associated with increased risk of type 2 diabetes (OR per allele 1·02, 95% CI 1·00-1·05; p=0·09; fi gures 1E and 2). Data on the association between HMGCR rs12916 and type 2 diabetes were available for 14 976 cases and 74 395 controls (16 studies). The OR per rs12916-T allele was 1·06 (95% CI 1·03-1·09; p=9·58 × 10 -⁵). The associations of both SNPs were confi rmed when our data were combined in a metaanalysis with those from a large genome-wide association and Metabochip study of risk of type 2 diabetes (rs17238484 OR 1·03, 95% CI 1·01-1·06; rs12916 1·02, 1·00-1·04; appendix). 31
Figure 2: Meta-analyses of the associations of 3-hydroxy-3-methylglutaryl-CoA reductase variants rs17238484 and rs12916 with risk of type 2 diabetes
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Data from 129 170 participants free from type 2 diabetes at baseline were available from 20 statin trials (table) There was no association between LDL cholesterol lowering at 1 year and within-trial ORs for new-onset type 2 diabetes (log-odds per 1% reduction in LDL cholesterol 0·004, 95% CI -0·001 to 0·009; p=0·10; appendix), or between duration of follow-up and risk of type 2 diabetes in either univariate meta-regression (log odds per year increase in trial duration -0·021, 95% CI -0·058 to 0·017; p=0·26), or after adjustment for trial type (ie, placebo-controlled and standard care-controlled or intensive vs moderate statin dose) and percent LDL cholesterol change (log odds -0·006, -0·051 to 0·039; p=0·77). Data on the eff ect of statin treatment on bodyweight were available from 15 trials, including 91 393 participants free from type 2 diabetes at baseline. Mean follow-up was 3·9 years (range 1·9-5·9). Recipients of statin treatment or intensive-dose statin treatment were 0·24 kg (95% CI 0·10-0·38) heavier by the end of follow-up than were control recipients in a random-eff ects meta-analysis (fi gure 4), although there was substantial heterogeneity between trials (I² 78·6%, 95% CI 65·3-86·8). The appendix provides fi xed-eff ects meta-analysis estimates. When limited to individuals not experiencing a cardiovascular event, estimates were similar (0·21 kg, 95% CI 0·08-0·35; 83 959 individuals). The eff ect on bodyweight change was noted only in trials comparing statin treatment with placebo or standard care (0·33 kg, 95% CI 0·25 to 0·42; I² 18·6%), but not in trials comparing moderate-dose with intensive-dose statin treatment (-0·15 kg, 95% CI -0·39 to 0·08; I² 63·2%). No association was noted between relative LDL cholesterol reduction and within-trial bodyweight change (meta-regression β 0·004, 95% CI -0·012 to 0·021; p=0·58; appendix). There was no relation between duration of follow-up and bodyweight change in either univariate meta-regression (β -0·028 kg/year, 95% CI -0·147 to 0·092; p=0·63) or multivariate meta-regression analysis (β -0·009, 95% CI -0·091 to 0·073; p=0·81) after adjustment for relative LDL cholesterol change and trial type. No relation was noted between bodyweight change and risk of new-onset type 2 diabetes across the trials (log-odds per 1 kg bodyweight increase -0·14, 95% CI -0·41 to 0·13; p=0·29).
Discussion
HMGCR genetic variants in population studies and statin treatment in trials were associated with higher bodyweight and higher risk of type 2 diabetes, suggesting that these eff ects are a consequence of HMGCR 
Higher odds of type 2 diabetes in the treatment arm Lower odds of type 2 diabetes in the treatment arm inhibition. The association of HMGCR SNPs with risk of type 2 diabetes is new, as is the association of statin treatment and HMGCR SNPs with increased bodyweight. Increased bodyweight plays a causal part in the development of type 2 diabetes, 33 suggesting a possible mechanism for the dysglycaemic eff ect of statin treatment. However, whether the relation between HMGCR inhibition and type 2 diabetes is mediated exclusively by changes in body composition remains unknown. Statin treatment led to higher bodyweight and increased risk of type 2 diabetes, and both HMGCR SNPs studied were associated with higher bodyweight and waist circumference, and one with higher plasma insulin and glucose concentrations. Insulin resistance might accompany bodyweight gain and a central distribution of adipose tissue. However, we were unable to identify a specifi c association of statin treatment with insulin resistance in these analyses because the relevant measures were unavailable from trials. One small trial 34 that was ineligible for the present study reported 2 months of atorvastatin treatment led to higher glycated haemoglobin (HbA 1c ) and insulin concentrations and lower insulin sensitivity than with placebo, and fi ndings from a previous meta-analysis 35 of statin trials suggested diff erential eff ects on insulin sensitivity between statins. In JUPITER 36 and PROVE-IT TIMI 22, 37 small increases in HbA 1c were noted in individuals randomly assigned to statin treatment compared with control individuals, and in AFORRD, 38 HbA 1c also increased slightly in patients on atorvastatin compared with placebo after 4 months. Nevertheless, the association of one HMGCR SNP with fasting insulin and glucose concentrations, and its attenuation to the null after adjustment for BMI, support a bodyweight-mediated association between HMGCR inhibition and insulin resistance as a possible mechanistic explanation. Conversely, the magnitude of bodyweight gain we noted in both statin trials and genetic studies seems insuffi cient to account for the corresponding risk of type 2 diabetes. Intensive statin treatment also showed no greater eff ect on bodyweight than low-dose or moderate-dose treatment, although type 2 diabetes risk was greater with intensive statin treatment.
The anatomical site of the genetic and drug eff ects on energy metabolism that we report is not completely certain. The liver is a likely location, in view of its important involvement in lipid metabolism; however, the dysglycaemic phenotypes reported here might be caused by modulation of HMGCR function in skeletal muscle. Additional, off -target eff ects of statins might also make a further contribution to bodyweight gain. 39 Inhibition of HMGCR by statins impairs hepatocyte cholesterol synthesis, upregulates hepatic LDL receptor expression, and reduces circulating LDL cholesterol concentrations. Although the genetic fi ndings provide evidence that the eff ect of statins on bodyweight and type 2 diabetes risk is caused by HMGCR inhibition, whether this eff ect requires or is independent of reductions in circulating LDL cholesterol remains unclear. A meta-regression analysis of trial data did not provide evidence for an association between LDL cholesterol reduction and bodyweight or type 2 diabetes risk, but these analyses were done with summary-level data, which might have limited our ability to detect any such relation. Studies of genetic variants from other loci Figure 4 : Eff ect of statin treatment on bodyweight Data were analysed by random-eff ects meta-analysis. In most trials, the total number of participants without type 2 diabetes at baseline for whom bodyweight data were available was smaller than the total number for whom data were available for the analysis of new-onset type 2 diabetes. Overall (I 2 =78·6%, p<0·0001) Note: weights are from random-effects analysis 0·42 (0·07 to 0·77) 0·31 (0·06 to 0·56) 0·41 (0·19 to 0·63) 0·60 (0·08 to 1·12) 0·31 (0·04 to 0·58) 0·44 (0·17 to 0·71) 0·29 (0·05 to 0·53) -0·10 (-0·49 to 0·29) 0·18 (0·00 to 0·36) 0·30 (-0·07 to 0·67) 0·40 (0·23 to 0·57) 0·72 (0·28 to 1·16) 0·33 (0·25 to 0·42) An association with BMI has been identifi ed for a SNP 350 kb from HMGCR at a genome-wide level of signifi cance (p=2·17 × 10 -¹³), 29 although with no other variants within the HMGCR gene. In publicly available data from two genomewide association studies, [29] [30] associations of the rs17238484 and rs12916 with BMI and plasma insulin concentration were noted at strong but sub-genome-wide levels of signifi cance. This evidence, the consistent eff ect of both SNPs on LDL cholesterol, and a specifi c association with hepatocyte HMGCR mRNA expression for one of the SNPs (rs12916; appendix) supports their validity as genetic instruments in this analysis.
We used two HMGCR SNPs in the genetic analysis, one for the main (rs17238484) and another (rs12916) for a subsidiary analysis. Although the fi ndings were broadly consistent, the small diff erences in eff ect estimates between the two variants could be caused by the diff erent allele frequencies, available sample size for each, and the association of each with a functional variant or variants that were not identifi ed.
This study has some limitations. Not all phenotypes measured in genetic studies were available in the statin trials-notably plasma glucose and insulin, waist and hip circumference, and waist:hip ratio. Moreover, not all studies in the genetic analysis measured glucose in fasting samples. In view of the wide age range of participants included in these analyses, survival bias might have aff ected our fi ndings; however, this is unlikely and any such eff ect, if present, would probably have been limited. The HMGCR variants might aff ect the odds of being prescribed lipid-lowering drugs and thus introduce bias to the association between HMGCR and risk of type 2 diabetes. However, we found no evidence of an interaction between genotype, lipid-lowering drug use at study baseline, and risk of type 2 diabetes (appendix). The source of the heterogeneity between the statin trials that provided bodyweight data, particularly for dose-comparison trials, remains uncertain. Reductions in LDL cholesterol between arms in the dose comparison trials was smaller than that achieved in the placebocontrolled trials. Our analysis was restricted to participants without type 2 diabetes at baseline. However, we did not have access to data on within-trial death, withdrawal, or loss to follow-up. Although observational pharmacoepidemiological studies have also examined the association of statin prescription with the development of type 2 diabetes, studies of this type can be prone to confounding and bias. For this reason, and to permit more direct comparison with the genetic analysis, we focused on data from randomised trials. Finally, trial analyses were done with summary-level data, which limited power for meta-regression.
Our fi ndings pertain to the mechanism by which statins slightly increase the risk of type 2 diabetes-an association that has already been established. Findings from recent analyses of trials have shown that, although this association is robust, the absolute risk of developing type 2 diabetes is greatly off set by the benefi ts of statin treatment for CVD risk. 3, 40 Indeed, the effi cacy of statin treatment to reduce the risk of CVD has been shown conclusively in several large primary and secondary prevention randomised controlled trials, including in individuals with type 2 diabetes, with a favourable risk:benefi t profi le. 1, 3, 4 For this reason, our fi ndings provide mechanistic insight, but should not alter present guidance on prescription of statins for prevention of CVD. Nevertheless, our results, including the new fi nding of increased bodyweight with statin treatment, suggest lifestyle interventions such as bodyweight optimisation, healthy diet, and adequate physical activity should be emphasised as important adjuncts to prevention of CVD with statin treatment to attenuate risks of type 2 diabetes. The reason why bodyweight change does not seem to be greater with intensive statin treatment compared with moderate-dose treatment needs further investigation.
In conclusion, both statin treatment in randomised trials and carriage of common SNPs in the HMGCR gene in population studies were associated with bodyweight gain and higher risk of type 2 diabetes. Bodyweight gain is physiologically linked to insulin resistance and is one of the strongest risk factors for type 2 diabetes, which might partly explain the higher risk of type 2 diabetes in statin-treated patients.
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